Loading stock…

Precigen, Inc. (PGEN) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Precigen, Inc.

PGENMarket cap $2.70BPrice $7.5

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Develops precision gene and cell therapies targeting rare diseases and cancers most biotech companies won't touch. Its lead therapy for a rare respiratory condition just won FDA approval, turning decades of genetic engineering research into an actual commercial product.

In Bastion Portfolios?

52W Return+89%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)-29%1

Revenue Forecast

Rev CAGR (1y)+2304%10

Rev CAGR (3y)+276%10

Rev CAGR (5y)+152%10

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+434%10

EPS Growth Y+3+84%10

Quality

Margins

EBIT Margin-46%1

Net Income Margin-184%1

Free Cash Flow Margin-134%1

Debt

Net Debt/EBITDAna–

Efficiency

ROE-1545%1

ROA-116%1

Earnings Stability44

GEAR+WEAK22

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)761

P/E Ratio (Forward 3y)136

P/BV62.01

EV Multiples

EV/EBITDA Fwdna–

EV/EBIT Fwd272

Yield

Free Cash Flow Yield-4.3%2

Dividend Yieldna–

Momentum

Short term

1 month return+6%9

3 month return+37%10

YTD return+81%10

Mid term

Price vs 52wHigh84%6

1 year return+128%10

Long term

3 year return+455%10

5 year return+58%6

Risk Shield

Price Risk

Beta1.62

Volatility78%1

Free Cash Flow

Free Cash Flow Margin-134%1

Free Cash Flow Yield-4.3%2

Quality

ROCE-36%1

Earnings Stability44

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

PGENPrecigen

Revenue FY25$10M

GROWTH RATING↗

VERY STRONG92 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-29%1

Revenue, next 1Y+2304%10

Revenue, next 3Y, CAGR+276%10

Revenue, next 5Y, CAGR+152%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+434%10

EPS growth, FY28E+84%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 92% of companies worldwide.

Revenue is set to grow 276%/yr over the next 3 years, ahead of most of the market.10/10

After shrinking over the last 3 years, revenue is set to grow 276%/yr from here.

The runway holds up: revenue is set to grow 152%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

Revenue fell 29%/yr over the last 3 years, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG92 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return+37%10

YTD return+81%10

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+128%10

3-year return+455%10

5-year return+58%6

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +455% over three years and +58% over five, ahead of 70% of the market.

It's up 128% over the past year, but 16% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+6%), over three months (+37%) and so far this year (+81%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Precigen, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

PGENPrecigen

Revenue FY25$10M

GROWTH RATING↗

VERY STRONG92 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR-29%1

Revenue, next 1Y+2304%10

Revenue, next 3Y, CAGR+276%10

Revenue, next 5Y, CAGR+152%10

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+434%10

EPS growth, FY28E+84%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 92% of companies worldwide.

Revenue is set to grow 276%/yr over the next 3 years, ahead of most of the market.10/10

After shrinking over the last 3 years, revenue is set to grow 276%/yr from here.

The runway holds up: revenue is set to grow 152%/yr over five years.10/10

WATCH

None flagged.

WEAKNESSES

Revenue fell 29%/yr over the last 3 years, behind 90% of companies worldwide.1/10

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that's turning around. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

VERY STRONG92 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return+37%10

YTD return+81%10

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return+128%10

3-year return+455%10

5-year return+58%6

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +455% over three years and +58% over five, ahead of 70% of the market.

It's up 128% over the past year, but 16% below its 52-week high. That is clearly ahead of the market.

Strong recent results. The stock is outperforming over the past month (+6%), over three months (+37%) and so far this year (+81%).

WATCH

None flagged.

WEAKNESSES

None flagged.

BOTTOM LINE

Momentum Leader

Short- and long-term returns both rank among the best globally. The market is behind it — a core fit for momentum strategies.

04Value

Are you paying a fair price for it?

Stop guessing on Precigen, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community